Topoisomerase IIα in chromosome instability and personalized cancer therapy

Oncogene

Volumn 34, Issue 31, 2015, Pages 4019-4031

  Chen, T ^a,b   Sun, Y ^c   Ji, P ^a   Kopetz, S ^a   Zhang, W ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b FUDAN UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRG1 PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MITOXANTRONE; TENIPOSIDE; TOPOISOMERASE II ALPHA; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; GYRASE INHIBITOR; TUMOR ANTIGEN;

CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CHROMOSOME SEGREGATION; DEACETYLATION; DNA BINDING; ENZYME ACTIVITY; GENE DOSAGE; GENOMIC INSTABILITY; HUMAN; NEOPLASM; NONHUMAN; PERSONALIZED CANCER THERAPY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SUMOYLATION; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; GENETICS; NEOPLASMS; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; CHROMOSOMAL INSTABILITY; CHROMOSOME SEGREGATION; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; HUMANS; NEOPLASMS; PRECISION MEDICINE; TOPOISOMERASE II INHIBITORS;

EID: 84938500108     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.332     Document Type: Review

References (164)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649.
3. Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. Defining 'chromosomal instability'. Trends Genet 2008; 24: 64-69.
4. Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol 2005; 15: 43-49.
5. Chen J, Fu L, Zhang LY, Kwong DL, Yan L, Guan XY. Tumor suppressor genes on frequently deleted chromosome 3p in nasopharyngeal carcinoma. Chin J Cancer 2012; 31: 215-222.
6. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005; 5: 773-785.
7. Duijf PH, Benezra R. The cancer biology of whole-chromosome instability. Oncogene 2013; 32: 4727-4736.
8. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K et al. Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J Clin Oncol 2012; 30: 2256-2264.
9. Wang X. Discovery of molecular associations among aging, stem cells, and cancer based on gene expression profiling. Chin J Cancer 2013; 32: 155-161.
10. Parker BC, Zhang W. Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment. Chin J Cancer 2013; 32: 594-603.
11. Duesberg P, Li R. Multistep carcinogenesis: a chain reaction of aneuploidizations. Cell Cycle 2003; 2: 202-210.
12. Barber TD, McManus K, Yuen KW, Reis M, Parmigiani G, Shen D et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci USA 2008; 105: 3443-3448.
13. Peters JM. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell 2002; 9: 931-943.
14. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001; 70: 369-413.
15. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-440.
16. Sumner AT. Inhibitors of topoisomerase II delay progress through mitosis and induce doubling of the DNA content in CHO cells. Exp Cell Res 1995; 217: 440-447.
17. Chen M, Beck WT. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 1993; 53: 5946-5953.
18. Cummings J, Sumner AT, Slavotinek A, Meikle I, Macpherson JS, Smyth JF. Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenylamino acid topoisomerase II catalytic inhibitor NU/ICRF 500. Mutat Res 1995; 344: 55-62.
19. Sumner AT. Induction of diplochromosomes in mammalian cells by inhibitors of topoisomerase II. Chromosoma 1998; 107: 486-490.
20. Ferguson LR, Whiteside G, Holdaway KM, Baguley BC. Application of fluorescence in situ hybridization to study the relationship between cytotoxicity, chromosome aberration, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine. Environ Mol Mutagen 1998; 27: 255-262.
21. Kallio M, Lahdetie J. Effects of DNA topoisomerase inhibitor merbarone in male mouse meiotic divisions in vivo: cell cycle arrest and induction of aneuploidy. Environ Mol Mutagen 1997; 29: 16-27.
22. Holm C. Coming undone: how to untangle a chromosome. Cell 1994; 77: 955-957.
23. Deming PB, Cistulli CA, Zhao H, Graves PR, Piwnica-Worms H, Paules RS et al. The human decatenation checkpoint. Proc Natl Acad Sci USA 2001; 98: 12044-12049.
24. Downes CS, Clarke DJ, Mullinger AM, Giménez-Abián JF, Creighton AM, Johnson RT. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 1994; 372: 467-470.
25. Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell 1997; 88: 315-321.
26. Schmidt BH, Burgin AB, Deweese JE, Osheroff N, Berger JM. A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature 2010; 465: 641-644.
27. Schmidt BH, Osheroff N, Berger JM. Structure of a topoisomerase II-DNAnucleotide complex reveals a new control mechanism for ATPase activity. Nat Struct Mol Biol 2012; 19: 1147-1154.
28. Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM. The structure of DNAbound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol 2012; 424: 109-124.
29. Villman K, Stahl E, Liljegren G, Tidefelt U, Karlsson MG. Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol 2002; 15: 486-491.
30. Cortes F, Pastor N, Mateos S, Dominguez I. Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutat Res 2003; 543: 59-66.
31. Yanagida M. Basic mechanism of eukaryotic chromosome segregation. Philos Trans R Soc Lond B Biol Sci 2005; 360: 609-621.
32. Wang LH, Schwarzbraun T, Speicher MR, Nigg EA. Persistence of DNA threads in human anaphase cells suggests late completion of sister chromatid decatenation. Chromosoma 2008; 117: 123-135.
33. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994; 91: 1781-1785.
34. Andoh T, Sato M, Narita T, Ishida R. Role of DNA topoisomerase II in chromosome dynamics in mammalian cells. Biotechnol Appl Biochem 1993; 18: 165-174.
35. Ishida R, Sato M, Narita T, Utsumi KR, Nishimoto T, Morita T et al. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J Cell Biol 1994; 126: 1341-1351.
36. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991; 51: 4909-4916.
37. Hasinoff BB, Abram ME, Barnabé N, Khélifa T, Allan WP, Yalowich JC. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol 2001; 59: 453-461.
38. Akimitsu N, Adachi N, Hirai H, Hossain MS, Hamamoto H, Kobayashi M et al. Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIαlpha. Genes Cells 2003; 8: 393-402.
39. Akimitsu N, Adachi N, Hirai H, Hossain MS, Hamamoto H, Kobayashi M et al. DNA topoisomerase IIbeta and neural development. Science 2000; 287: 131-134.
40. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. Pombe. Cell 1987; 50: 817-925.
41. Clarke DJ, Johnson RT, Downes CS. Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks. J Cell Sci 1993; 105: 563-568.
42. Carpenter AJ, Porter AC. Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIα mutant human cell line. Mol Biol Cell 2004; 15: 5700-5711.
43. Johnson M, Phua HH, Bennett SC, Spence JM, Farr CJ. Studying vertebrate topoisomerase 2 function using a conditional knockdown system in DT40 cells. Nucleic Acids Res 2009; 37: e98.
44. Chang CJ, Goulding S, Earnshaw WC, Carmena M. RNAi analysis reveals an unexpected role for topoisomerase II in chromosome arm congression to a metaphase plate. J Cell Sci 2003; 116: 4715-4726.
45. Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M et al. p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Nucleic Acids Res 1996; 24: 4464-4470.
46. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase IIalpha gene expression by the p53 tumor suppressor. Mol Cell Biol 1997; 17: 389-397.
47. Liu D, Huang CL, Kameyama K, Hayashi E, Yamauchi A, Sumitomo S et al. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. Cancer 2002; 94: 2239-2247.
48. Wang H, Jiang ZG, Wong YW, Dalton WS, Futscher BW, Chan VT. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem Biophys Res Commun 1997; 237: 217-224.
49. Belluti S, Basile V, Benatti P, Ferrari E, Marverti G, Imbriano C. Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-Demethoxy Curcumin in cancer cells. Cell Death Dis 2013; 4: e756.
50. Stros M, Polanská E, Struncová S, Pospísilová S. HMGB1 and HMGB2 proteins upregulate cellular expression of human topoisomerase IIalpha. Nucleic Acids Res 2009; 37: 2070-2086.
51. Williams AO, Isaacs RJ, Stowell KM. Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions. BMC Mol Biol 2007; 8: 36.
52. Mo YY, Wang Q, Beck WT. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3. Cancer Res 1997; 57: 5004-5008.
53. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994; 303: 681-695.
54. Ishida R, Iwai M, Marsh KL, Austin CA, Yano T, Shibata M et al. Threonine 1342 in human topoisomerase IIαlpha is phosphorylated throughout the cell cycle. J Biol Chem 1996; 271: 30077-30082.
55. Daum JR, Gorbsky GJ. Casein kinase II catalyzes a mitotic phosphorylation on threonine 1342 of human DNA topoisomerase IIαlpha, which is recognized by the 3F3/2 phosphoepitope antibody. J Biol Chem 1998; 273: 30622-30629.
56. Escargueil AE, Plisov SY, Filhol O, Cochet C, Larsen AK. Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469. J Biol Chem 2000; 275: 34710-34718.
57. Redwood C, Davies SL, Wells NJ, Fry AM, Hickson ID. Casein kinase II stabilizes the activity of human topoisomerase II α in a phosphorylation-independent manner. J Biol Chem 1998; 273: 3635-3642.
58. Luo K, Yuan J, Chen J, Lou Z. Topoisomerase IIαlpha controls the decatenation checkpoint. Nat Cell Biol 2009; 11: 204-210.
59. Chikamori K, Grabowski DR, Kinter M, Willard BB, Yadav S, Aebersold RH et al. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J Biol Chem 2003; 278: 12696-12702.
60. Sahyoun N, Wolf M, Besterman J, Hsieh T, Sander M, LeVine H 3rd et al. Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci USA 1986; 83: 1603-1607.
61. Shapiro PS, Whalen AM, Tolwinski NS, Wilsbacher J, Froelich-Ammon SJ, Garcia M et al. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol 1999; 19: 3551-3560.
62. Qi X, Hou S, Lepp A, Li R, Basir Z, Lou Z, Chen G. Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons. J Biol Chem 2011; 286: 35883-35890.
63. Li H, Wang Y, Liu X. Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression. J Biol Chem 2008; 283: 6209-6221.
64. Iida M, Matsuda M, Komatani H. Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that is not recognized by Plk1. Biochem J 2008; 411: 27-32.
65. Ganapathi RN, Ganapathi MK. Mechanisms regulating resistance to inhibitors of topoisomerase II. Front Pharmacol 2013; 4: 89.
66. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306: 1557-1565.
67. Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 2001; 28: 266-271.
68. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999; 22: 37-43.
69. Lou Z, Minter-Dykhouse K, Chen J. BRCA1 participates in DNA decatenation. Nat Struct Mol Biol 2005; 12: 589-593.
70. Wang RH, Yu H, Deng CX. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci USA 2004; 101: 17108-17113.
71. Shinagawa H, Miki Y, Yoshida K. BRCA1-mediated ubiquitination inhibits topoisomerase II alpha activity in response to oxidative stress. Antioxid Redox Signal 2008; 10: 939-949.
72. Gilmore PM, Quinn JE, Mullan PB, Andrews HN, McCabe N, Carty M et al. Role played by BRCA1 in regulating the cellular response to stress. Biochem Soc Trans 2003; 31: 257-262.
73. Azuma Y, Arnaoutov A, Dasso M. SUMO-2/3 regulates topoisomerase II in mitosis. J Cell Biol 2003; 163: 477-487.
74. Diaz-Martinez LA, Gimenez-Abian JF, Azuma Y, Guacci V, Gimenez-Martin G, Lanier LM et al. PIASgamma is required for faithful chromosome segregation in human cells. PloS One 2006; 1: e53.
75. Obado SO, Bot C, Echeverry MC, Bayona JC, Alvarez VE, Taylor MC et al. Centromere-associated topoisomerase activity in bloodstream form Trypanosoma brucei. Nucleic Acids Res 2011; 39: 1023-1033.
76. Azuma Y. Analysis of SUMOylation of topoisomerase IIalpha with Xenopus egg extracts. Methods Mol Biol 2009; 582: 221-231.
77. Azuma Y, Arnaoutov A, Anan T, Dasso M. PIASy mediates SUMO-2 conjugation of Topoisomerase-II on mitotic chromosomes. EMBO J 2005; 24: 2172-2182.
78. Takahashi Y, Yong-Gonzalez V, Kikuchi Y, Strunnikov A. SIZ1/SIZ2 control of chromosome transmission fidelity is mediated by the sumoylation of topoisomerase II. Genetics 2006; 172: 783-794.
79. Díaz-Martínez LA, Giménez-Abián JF, Azuma Y, Guacci V, Giménez-Martín G, Lanier LM et al. PIASgamma is required for faithful chromosome segregation in human cells. PLoS One 2006; 1: e53.
80. Dawlaty MM, Malureanu L, Jeganathan KB, Kao E, Sustmann C, Tahk S et al. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIαlpha. Cell 2008; 133: 103-115.
81. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000; 26: 349-353.
82. Varga-Weisz PD, Wilm M, Bonte E, Dumas K, Mann M, Becker PB. Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature 1997; 388: 598-602.
83. Dykhuizen EC, Hargreaves DC, Miller EL, Cui K, Korshunov A, Kool M et al. BAF complexes facilitate decatenation of DNA by topoisomerase IIα. Nature 2013; 497: 624-627.
84. Meng H, Chen R, Li W, Xu L, Xu L. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry. Pathol Int 2012; 62: 391-399.
85. Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D et al. Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol 2009; 22: 579-588.
86. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Mod Pathol 2000; 13: 542-547.
87. Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004; 39: 288-297.
88. Washiro M, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Sugimoto T et al. Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target. J Cancer Res Clin Oncol 2008; 134: 793-801.
89. Lan J, Huang HY, Lee SW, Chen TJ, Tai HC, Hsu HP et al. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma. Tumour Biol 2014; 35: 179-187.
90. Bhargava R, Lal P, Chen B. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005; 123: 889-895.
91. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9: 444-450.
92. Lee WY, Jin YT, Chang TW, Lin PW, Su IJ. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters. Histopathology 1999; 34: 106-112.
93. Seery LT, Knowlden JM, Gee JM, Robertson JF, Kenny FS, Ellis IO et al. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 1999; 84: 258-262.
94. Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan CA et al. A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer. BMC Cancer 2014; 14: 421.
95. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
96. Lynch HT, Deters CA, Snyder CL, Lynch JF, Villeneuve P, Silberstein J et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 2005; 158: 119-125.
97. Gunduz E, Gunduz M, Nagatsuka H, Beder L, Demircan K, Tamamura R et al. Epigenetic alterations of BRG1 leads to cancer development through its nuclear-cytoplasmic shuttling abnormalities. Med Hypotheses 2006; 67: 1313-1316.
98. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 2008; 29: 617-622.
99. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003; 63: 560-566.
100. Glaros S, Cirrincione GM, Palanca A, Metzger D, Reisman D. Targeted knockout of BRG1 potentiates lung cancer development. Cancer Res 2008; 68: 3689-3696.
101. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M et al. Convergent structural alterations define Switch/sucrose nonfermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci USA 2012; 109: E252-E259.
102. Dal Molin M, Hong SM, Hebbar S, Sharma R, Scrimieri F, de Wilde RF et al. Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Hum Pathol 2012; 43: 585-591.
103. Li Y, Xiong H, Yang DQ. Functional switching of ATM: sensor of DNA damage in proliferating cells and mediator of Akt survival signal in post-mitotic human neuron-like cells. Chin J Cancer 2012; 31: 364-372.
104. Bower JJ, Karaca GF, Zhou Y, Simpson DA, Cordeiro-Stone M, Kaufmann WK. Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling. Oncogene 2010; 29: 4787-4799.
105. Hande KR. Topoisomerase II inhibitors. Update Cancer Ther 2008; 3: 13-26.
106. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9: 338-350.
107. Chen M, Beck WT. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol Res 1995; 7: 103-111.
108. Ritke MK, Murray NR, Allan WP, Fields AP, Yalowich JC. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. Mol Pharmacol 1995; 48: 798-805.
109. Kolb RH, Greer PM, Cao PT, Cowan KH, Yan Y. ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation. PLoS One 2012; 7: e50281.
110. Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res 2005; 65: 10265-10272.
111. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338: 359-363.
112. de Voer RM, Geurts van Kessel A, Weren RD, Ligtenberg MJ, Smeets D, Fu L et al. Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are risk factors for colorectal cancer. Gastroenterology 2013; 145: 544-547.
113. Jallepalli PV, Waizenegger IC, Bunz F, Langer S, Speicher MR, Peters JM et al. Securin is required for chromosomal stability in human cells. Cell 2001; 105: 445-457.
114. Tang Z, Shu H, Oncel D, Chen S, Yu H. Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle checkpoint. Mol Cell 2004; 16: 387-397.
115. Jeganathan K, Malureanu L, Baker DJ, Abraham SC, van Deursen JM. Bub1 mediates cell death in response to chromosome mis-segregation and acts to suppress spontaneous tumorigenesis. J Cell Biol 2007; 179: 255-267.
116. Baker DJ, Jeganathan KB, Cameron JD, Thompson M, Juneja S, Kopecka A et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet 2004; 36: 744-749.
117. Taylor SS, Ha E, McKeon F. The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase. J Cell Biol 1998; 142: 1-11.
118. Chen RH, Shevchenko A, Mann M, Murray AW. Spindle checkpoint protein Xmad1 recruits Xmad2 to unattached kinetochores. J Cell Biol 1998; 143: 283-295.
119. Fang G, Yu H, Kirschner MW. The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev 1998; 12: 1871-1883.
120. Luo X, Fang G, Coldiron M, Lin Y, Yu H, Kirschner MW et al. Structure of the Mad2 spindle assembly checkpoint protein and its interaction with Cdc20. Nat Struct Biol 2000; 7: 224-229.
121. Weaver BA, Bonday ZQ, Putkey FR, Kops GJ, Silk AD, Cleveland DW. Centromereassociated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss. J Cell Biol 2003; 162: 551-563.
122. Habu T, Kim SH, Weinstein J, Matsumoto T. Identification of a MAD2-binding protein, CMT2, and its role in mitosis. EMBO J 2002; 21: 6419-6428.
123. Xia G, Luo X, Habu T, Rizo J, Matsumoto T, Yu H. Conformation-specific binding of p31(comet) antagonizes the function of Mad2 in the spindle checkpoint. EMBO J 2004; 23: 3133-3143.
124. London N, Biggins S. Mad1 kinetochore recruitment by Mps1-mediated phosphorylation of Bub1 signals the spindle checkpoint. Genes Dev 2014; 28: 140-152.
125. Tipton AR, Ji W, Sturt-Gillespie B, Bekier ME 2nd, Wang K, Taylor WR et al. Monopolar spindle 1 (MPS1) kinase promotes production of closed MAD2 (C-MAD2) conformer and assembly of the mitotic checkpoint complex. J Biol Chem 2013; 288: 35149-35158.
126. Kops GJ, Kim Y, Weaver BA, Mao Y, McLeod I, Yates JR 3rd et al. ZW10 links mitotic checkpoint signaling to the structural kinetochore. J Cell Biol 2005; 169: 49-60.
127. Lin YT, Chen Y, Wu G, Lee WH. Hec1 sequentially recruits Zwint-1 and ZW10 to kinetochores for faithful chromosome segregation and spindle checkpoint control. Oncogene 2006; 25: 6901-6914.
128. Buffin E, Lefebvre C, Huang J, Gagou ME, Karess RE. Recruitment of Mad2 to the kinetochore requires the Rod/Zw10 complex. Curr Biol 2005; 15: 856-861.
129. Williams BC, Li Z, Liu S, Williams EV, Leung G, Yen TJ et al. Zwilch, a new component of the ZW10/ROD complex required for kinetochore functions. Mol Biol Cell 2003; 14: 1379-1391.
130. Wirth KG, Wutz G, Kudo NR, Desdouets C, Zetterberg A, Taghybeeglu S et al. Separase: a universal trigger for sister chromatid disjunction but not chromosome cycle progression. J Cell Biol 2006; 172: 847-860.
131. Ricke RM, van Ree JH, van Deursen JM. Whole chromosome instability and cancer: a complex relationship. Trends Genet 2008; 24: 457-466.
132. Sudakin V, Chan GK, Yen TJ. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 2001; 154: 925-936.
133. Nilsson J, Yekezare M, Minshull J, Pines J. The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. Nat Cell Biol 2008; 10: 1411-1420.
134. Jeganathan KB, Baker DJ, van Deursen JM. Securin associates with APC (Cdh1) in prometaphase but its destruction is delayed by Rae1 and Nup98 until the metaphase/anaphase transition. Cell Cycle 2006; 5: 366-370.
135. García-Higuera I, Manchado E, Dubus P, Cañamero M, Méndez J, Moreno S et al. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol 2008; 10: 802-811.
136. Coelho PA, Queiroz-Machado J, Carmo AM, Moutinho-Pereira S, Maiato H, Sunkel CE. Dual role of topoisomerase II in centromere resolution and aurora B activity. PloS Biol 2008; 6: e207.
137. Privette LM, Weier JF, Nguyen HN, Yu X, Petty EM. Loss of CHFR in human mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint. Neoplasia 2008; 10: 643-652.
138. Giménez-Abián JF, Sumara I, Hirota T, Hauf S, Gerlich D, de la Torre C et al. Regulation of sister chromatid cohesion between chromosome arms. Curr Biol 2004; 14: 1187-1193.
139. Huang B, Shang ZF, Li B, Wang Y, Liu XD, Zhang SM et al. The catalytic subunit of DNA-dependent protein kinase associates with PLK1 and is involved in proper chromosome segregation and regulation of the cytokinesis. J Cell Biochem 2014; 115: 1077-1088.
140. Liu H, Jia L, Yu H. Phospho-H2A and cohesin specify distinct tension-regulated Sgo1 pools at kinetochores and inner centromeres. Curr Biol 2013; 23: 1927-1933.
141. Kaitna S, Mendoza M, Jantsch-Plunger V, Glotzer M. Incenp and an aurora-like kinase form a complex essential for chromosome segregation and efficient completion of cytokinesis. Curr Biol 2000; 10: 1172-1181.
142. Adams RR, Maiato H, Earnshaw WC, Carmena M. Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J Cell Biol 2001; 153: 865-880.
143. Lee BH, Amon A. Role of Polo-like kinase CDC5 in programming meiosis I chromosome segregation. Science 2003; 300: 482-486.
144. Kallio MJ, Nieminen M, Eriksson JE. Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J 2001; 15: 2721-2723.
145. Maney T, Hunter AW, Wagenbach M, Wordeman L. Mitotic centromereassociated kinesin is important for anaphase chromosome segregation. J Cell Biol 1998; 142: 787-801.
146. Prasanth SG, Prasanth KV, Stillman B. Orc6 involved in DNA replication, chromosome segregation, and cytokinesis. Science 2002; 297: 1026-1031.
147. Ji P, Smith SM, Wang Y, Jiang R, Song SW, Li B et al. Inhibition of gliomagenesis and attenuation of mitotic transition by MIIP. Oncogene 2010; 29: 3501-3508.
148. Bhat UG, Raychaudhuri P, Beck WT. Functional interaction between human topoisomerase IIalpha and retinoblastoma protein. Proc Natl Acad Sci USA 1999; 96: 7859-7864.
149. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112.
150. Yamasaki L. Role of the RB tumor suppressor in cancer. Cancer Treat Res 2003; 115: 209-239.
151. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
152. Li L, Davie JR. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 2010; 192: 275-283.
153. Lin WC, Yan MD, Yu PN, Li HJ, Kuo CC, Hsu CL et al. The role of Sp1 and EZH2 in the regulation of LMX1A in cervical cancer cells. Biochim Biophys Acta 2013; 1833: 3206-3217.
154. Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res 2013; 19: 4046-4057.
155. Chen J, Xi B, Zhao Y, Yu Y, Zhang J, Wang C. High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol 2012; 126: 109-117.
156. Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, Cao M et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol 2012; 106: 57-61.
157. Liu Y, Xie C, Zhang X, Huang D, Zhou X, Tan P et al. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 2010; 46: 3007-3015.
158. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008; 216: 167-175.
159. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24: 267-276.
160. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett 2006; 235: 1-10.
161. Qi X, Tang J, Loesch M, Pohl N, Alkan S, Chen G. p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion. Cancer Res 2006; 66: 7540-7547.
162. Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 2010; 119: 13-24.
163. Patel AN, Goyal S, Wu H, Schiff D, Moran MS, Haffty BG. Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 2011; 126: 601-607.
164. Yuan C, Bu Y, Wang C, Yi F, Yang Z, Huang X et al. NFBD1/MDC1 is a protein of oncogenic potential in human cervical cancer. Mol Cell Biochem 2012; 359: 333-346.